Profectus Ebola vaccine shown to be effective
The VesculoVax platform has demonstrated its efficacy against the Makona strain of the disease in animal models, the same one that is causing the current outbreak of the disease in West Africa.
Eight animals were used in the study, and those who received one of the two forms of the vaccine candidate were protected against symptoms and death.
"These data validate the Vesiculovax platform approach to delivery of immunogens against infectious diseases," Jeffrey Meshulam, president of Profectus, said. "More than 15 years have been invested in developing the genetically attenuated rVSVN4CT1 VesiculoVax vaccine delivery platform and demonstrating its safety and immunogenicity in multiple clinical trials. We are excited about its potential to improve the ability to address the current Ebola outbreak as well as other infectious disease outbreaks."
Support in the development of the platform came from the National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services and the Joint Vaccine Acquisition Program within the Department of Defense.
Such vaccine candidates are formed using genetically modified forms of vesiculovirus that have been rendered unable to infect individuals.